Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.
There are no real-world studies on the long-term effectiveness of anti-interleukin-23 antibody tildrakizumab in Japanese patients with psoriasis stratified by pretreatment status. To evaluate the 52-week real-world effectiveness of tildrakizumab for psoriasis patients, stratified by prior systemic therapy, prior biologic therapy, or prior deucravacitinib treatment, and to assess the maintenance of week 16 responses and achievement of delayed responses in patients without week 16 responses. This study included 57 patients with psoriasis treated with tildrakizumab. Psoriasis area and severity index (PASI) and static physician's global assessment (sPGA) were analyzed through week 52 in subgroups stratified by the presence or absence of prior systemic therapy, prior biologic therapy, or prior deucravacitinib treatment. Patients who achieved PASI 75, PASI 90, PASI 100, absolute PASI ≤ 3, absolute PASI ≤ 2, or sPGA 0/1 at week 16 were assessed for the maintenance of respective responses, and patients without week 16 responses were assessed for the achievement of delayed responses through week 52. Analyses were descriptive and used an as-observed approach. Tildrakizumab reduced PASI throughout 52 weeks regardless of the presence or absence of prior systemic therapy, prior biologic therapy, or prior deucravacitinib treatment. Responses achieved at week 16 were mostly maintained through week 52. Some patients without week 16 responses achieved delayed responses by week 52. Tildrakizumab reduced PASI throughout 52 weeks in patients with psoriasis regardless of prior systemic therapy, prior biologic therapy, or prior deucravacitinib treatment. Responses achieved at week 16 were mostly sustained through week 52. Some patients without week 16 responses could achieve delayed responses by week 52.
